Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Stanford University
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
mild or moderate to severe thyroid eye disease in one or both eyes
age \> 18 years
informed consent
intraocular pressure \> 21 mmHg or glaucoma suspect or glaucoma diagnosed in one or both eyes
not on current prostaglandin analog intraocular pressure lowering therapy
You may not be if
sight threatening thyroid eye disease
children \< 18 years old
patients that are not compliant with treatment or follow-up
patients already on prostaglandin analog treatment
patients that undergo cosmetic periocular procedures during the study will be excluded from further follow up
patients that cannot tolerate prostaglandin analog treatment.
patients with bilateral thyroid eye disease and elevated intraocular pressures that cannot tolerate treatment with timolol or an alternative intraocular pressure lowering medication such as trusopt, combigan, cosopt.
Clareo Health | The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients.
